Találati lista | Tudóstér

001-es BibID:	BIBFORM076676
035-os BibID:	(cikkazonosító)8670398 (WOS)000458978300001 (Scopus)85062331886
Első szerző:	Gergely Péter (igazságügyi orvosszakértő)
Cím:	Tyrosine kinase inhibitor Imatinib mesylate alters DMBA-induced early onco/suppressor-gene expression with tissue-specificity in mice / Péter Attila Gergely, Balázs Murnyák, János Bencze, Andrea Kurucz, Timea Varjas, Katalin Gombos, Tibor Hortobágyi
Dátum:	2019
ISSN:	2314-6133 2314-6141
Megjegyzések:	Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and widely-used drug molecules in targeted cancer therapies. Altered expressions of proto-oncogenes and tumor suppressor genes after DMBA (7,12- dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction, however their tissue-specific effects remain still unclear. Our study was aimed to examine the short-term possible anti-neoplastic and chemo-preventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. In addition, we also investigated the tissue specific expressions of Hras, Kras, Myc, Trp53 genes in the brain, bone marrow, spleen, liver, abdominal lymph nodes, thymus, lungs and kidneys, respectively. 24 hours after the imatinib mesylate injection, we observed significant Kras down-regulations in the bone marrow and lung of the DMBA-treated mice. Moreover, the mRNA expression of Myc was also found to be decreased significantly in the spleen. Interestingly, while Trp53 expression was significantly increased in the lung, it was decreased in the other tissues. However, there was also a tendency in the decreased Myc level in the bone marrow, brain, kidneys, lungs, lymph nodes, and in the decreased Hras level in the bone marrow, kidneys and lungs, although no significant differences were observed. Our findings indicate rapid tissue-specific impact of imatinib mesylate on DMBA-induced gene expression in vivo, supporting the chemo-preventive potential of imatinib mesylate in cancer.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	BioMed Research International. - 2019 (2019), p. 1-12. -
További szerzők:	Murnyák Balázs (1986-) (molekuláris biológus, genetikus) Bencze János (1991-) (orvos) Kurucz Andrea (1984-) (orvos) Varjas Tímea Gombos Katalin Hortobágyi Tibor (1965-) (patológus)
Pályázati támogatás:	2017-1.2.1-NKP-2017-00002 Egyéb UNKP-18-3 Egyéb EFOP-3.6.3-VEKOP-16-2017-00009 EFOP
Internet cím:	DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM059406
Első szerző:	Murnyák Balázs (molekuláris biológus, genetikus)
Cím:	Epigenetics of Meningiomas / Balázs Murnyák, László Bognár, Álmos Klekner, Tibor Hortobágyi
Dátum:	2015
ISSN:	2314-6133 2314-6141
Megjegyzések:	Meningiomas account for one-third of all adult central nervous system tumours and are divided into three WHO grades. In contrast to the relatively well characterized genetic alterations, our current understanding of epigenetic modifications involved in the meningioma-genesis and progression is rather incomplete. Contrary to genetic alterations, epigenetic changes do not alter the primary DNA sequence and their reversible nature serves as an excellent basis for prevention and development of novel personalised tumour therapies. Indeed, growing body of evidence suggests that disturbed epigenetic regulation plays a key role in the pathogenesis of meningiomas. Altered DNA methylation, microRNA expression, histone, and chromatin modifications are frequently noted in meningiomas bearing prognostic and therapeutic relevance. In this review we provide an overview on recently identified epigenetic alterations in meningiomas and discuss their role in tumour initiation, progression, and recurrence.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban HISTONE MODIFICATIONS MOLECULAR-GENETICS METHYLATION STATUS DOWN-REGULATION BRAIN-TUMORS ALLELIC LOSS CANCER MUTATIONS PROMOTER CLASSIFICATION
Megjelenés:	Biomed Research International. - 2015 (2015), p. 1-6. -
További szerzők:	Bognár László (1958-) (idegsebész, gyermekidegsebész) Klekner Álmos (1970-) (idegsebész) Hortobágyi Tibor (1965-) (patológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: